2023 - Research.com Medicine in Finland Leader Award
Heikki Joensuu focuses on Internal medicine, Pathology, Cancer, Oncology and Surgery. His study connects Gastroenterology and Internal medicine. His Pathology study combines topics in areas such as Angiogenesis and Metastasis.
His Cancer research is mostly focused on the topic Breast cancer. Heikki Joensuu interconnects Tumor-infiltrating lymphocytes, Clinical endpoint, Stage, Survival analysis and Risk factor in the investigation of issues within Oncology. His Surgery research integrates issues from GiST and Imatinib mesylate.
His primary areas of investigation include Internal medicine, Oncology, Breast cancer, Cancer and Cancer research. His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Surgery. His research investigates the link between Oncology and topics such as Docetaxel that cross with problems in Epirubicin.
His biological study spans a wide range of topics, including Gynecology and Pathology. His Cancer research research is multidisciplinary, incorporating perspectives in Immunohistochemistry, Tyrosine kinase, Carcinogenesis and Cancer cell. His Imatinib research includes elements of Stromal cell and Tyrosine-kinase inhibitor.
Heikki Joensuu spends much of his time researching Internal medicine, Oncology, Breast cancer, Cancer research and Cancer. His Oncology research incorporates elements of Capecitabine, Proportional hazards model, Triple-negative breast cancer, Docetaxel and Imatinib. His Breast cancer research includes themes of Stroma, Artificial intelligence and Pathology.
His Cancer research study integrates concerns from other disciplines, such as Immunohistochemistry, Apoptosis, Gene silencing and Drug resistance. His research investigates the connection between Cancer and topics such as Cell culture that intersect with issues in Cell growth. Heikki Joensuu has researched GiST in several fields, including Regorafenib, Clinical endpoint, Sarcoma and Imatinib mesylate.
Internal medicine, Oncology, Breast cancer, Cancer research and Cancer are his primary areas of study. In most of his Internal medicine studies, his work intersects topics such as Surgery. His Oncology study combines topics from a wide range of disciplines, such as Chemotherapy, Docetaxel, Imatinib mesylate, Young adult and GiST.
The various areas that Heikki Joensuu examines in his Breast cancer study include Receptor, Dose escalation, Proportional hazards model and Hazard ratio. The Cancer research study combines topics in areas such as Apoptosis and Advanced melanoma. His work in Cancer tackles topics such as Biomarker which are related to areas like Tyrosine-kinase inhibitor, Renal cell carcinoma, Gastroenterology and Downregulation and upregulation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele.
The New England Journal of Medicine (2002)
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke.
Journal of Clinical Oncology (2003)
Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
Heikki Joensuu;Peter J. Roberts;Maarit Sarlomo-Rikala;Leif C. Andersson.
The New England Journal of Medicine (2001)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Heikki Joensuu;Pirkko-Liisa Kellokumpu-Lehtinen;Petri Bono;Tuomo Alanko.
The New England Journal of Medicine (2006)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay.
The Lancet (2013)
Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
Charles D Blanke;George D Demetri;Margaret von Mehren;Michael C Heinrich.
Journal of Clinical Oncology (2008)
Risk stratification of patients diagnosed with gastrointestinal stromal tumor
Human Pathology (2008)
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Ari Ristimäki;Anna Sivula;Johan Lundin;Mikael Lundin.
Cancer Research (2002)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi;S. Loi;S. Michiels;S. Michiels;R. Salgado;N. Sirtaine.
Annals of Oncology (2014)
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Heikki Joensuu;Mikael Eriksson;Kirsten Sundby Hall;Jörg T. Hartmann.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: